PMID- 27842576 OWN - NLM STAT- MEDLINE DCOM- 20171003 LR - 20191210 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 16 IP - 1 DP - 2016 Nov 14 TI - Synthesis and bio-molecular study of (+)-N-Acetyl-alpha-amino acid dehydroabietylamine derivative for the selective therapy of hepatocellular carcinoma. PG - 883 LID - 883 AB - BACKGROUND: The purpose of present work is to synthesize novel (+)-Dehydroabietylamine derivatives (DAAD) using N-acetyl-alpha-amino acid conjugates and determine its cytotoxic effects on hepatocellular carcinoma cells. METHODS: An analytical study was conducted to explore cytotoxic activity of DAAD on hepatocellular carcinoma cell lines. The cytotoxicity effect was recorded using sulforhodamine B technique. Cell cycle analysis was performed using Propidium Iodide (PI) staining. Based on cell morphology, anti growth activity and microarray findings of DAAD2 treatment, Comet assay, Annexin V/PI staining, Immunoperoxidase assay and western blots were performed accoringly. RESULTS: Hep3B cells were found to be the most sensitive with IC(50) of 2.00 +/- 0.4 muM against (+)-N-(N-Acetyl-L-Cysteine)-dehydroabietylamine as DAAD2. In compliance to time dependent morphological changes of low cellular confluence, detachment and rounding of DAAD2 treated cells; noticeable changes in G(2)/M phase were recorded may be leading to cell cycle cessation. Up-regulation (5folds) of TUBA1A gene in Hep3B cells was determined in microarray experiments. Apoptotic mode of cell death was evaluated using standardized staining procedures including comet assay and annexin V/PI staining, Immuno-peroxidase assay. Using western blotting technique, caspase dependant apoptotic mode of cell death was recorded against Hep3B cell line. CONCLUSION: It is concluded that a novel DAAD2 with IC(50) values less than 8 muM can induce massive cell attenuation following caspase dependent apoptotic cell death in Hep3B cells. Moreover, the corelation study indicated that DAAD2 may have vital influence on cell prolifration properties. FAU - Mustufa, Muhammad Ayaz AU - Mustufa MA AD - 5th Floor, PHRC Specialized Research Centre on Child Health, National Institute of Child Health, Karachi, 75500, Pakistan. ayazbukero@gmail.com. AD - Baqai Institute of Pharmaceutical Sciences (BIPS), Baqai Medical University, Karachi, 74600, Pakistan. ayazbukero@gmail.com. AD - Department of Molecular, Biology and Genetics, BilGen Genetics and Biotechnology Center, Bilkent University, Ankara, 06800, Turkey. ayazbukero@gmail.com. FAU - Ozen, Cigdem AU - Ozen C AD - Izmir International Biomedicine and Genome Institute, iBG-izmir, Dokuz Eylul University, 35340, Balcova, Izmir, Turkey. FAU - Hashmi, Imran Ali AU - Hashmi IA AD - Department of Chemistry, University of Karachi, Karachi, 75270, Pakistan. FAU - Aslam, Afshan AU - Aslam A AD - Department of Chemistry, University of Karachi, Karachi, 75270, Pakistan. FAU - Baig, Jameel Ahmed AU - Baig JA AD - National Center of Excellence in Analytical Chemistry, University of Sindh, Jamshoro, 76080, Pakistan. FAU - Yildiz, Gokhan AU - Yildiz G AD - Department of Medical Biology, Erzincan University Faculty of Medicine, Erzincan, 24100, Turkey. FAU - Muhammad, Shoaib AU - Muhammad S AD - Department of Chemistry, University of Karachi, Karachi, 75270, Pakistan. FAU - Solangi, Imam Bakhsh AU - Solangi IB AD - Dr. M. A. Kazi Institute of Chemistry, University of Sindh, Jamshoro, 76080, Pakistan. FAU - Ul Hasan Naqvi, Naim AU - Ul Hasan Naqvi N AD - Baqai Institute of Pharmaceutical Sciences (BIPS), Baqai Medical University, Karachi, 74600, Pakistan. FAU - Ozturk, Mehmet AU - Ozturk M AD - Izmir International Biomedicine and Genome Institute, iBG-izmir, Dokuz Eylul University, 35340, Balcova, Izmir, Turkey. FAU - Ali, Firdous Imran AU - Ali FI AD - Department of Chemistry, University of Karachi, Karachi, 75270, Pakistan. firdousilyas@yahoo.com. LA - eng PT - Journal Article DEP - 20161114 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Abietanes) RN - 0 (Antineoplastic Agents) RN - 33289O147P (dehydroabietylamine) RN - EC 3.4.22.- (Caspases) SB - IM MH - Abietanes/*chemical synthesis/*pharmacology MH - Antineoplastic Agents/*chemical synthesis/*pharmacology MH - Apoptosis/drug effects MH - Carcinoma, Hepatocellular/genetics/metabolism MH - Caspases/metabolism MH - Cell Cycle/drug effects MH - Cell Line, Tumor MH - Cell Proliferation/drug effects MH - G2 Phase Cell Cycle Checkpoints/drug effects MH - Humans MH - Inhibitory Concentration 50 MH - Liver Neoplasms/genetics/metabolism PMC - PMC5109647 OTO - NOTNLM OT - Apoptosis OT - Connectivity map OT - Cytotoxicity OT - Dehydroabietylamine derivatives OT - Hepatocellular carcinoma EDAT- 2016/11/16 06:00 MHDA- 2017/10/04 06:00 PMCR- 2016/11/14 CRDT- 2016/11/16 06:00 PHST- 2016/04/24 00:00 [received] PHST- 2016/11/02 00:00 [accepted] PHST- 2016/11/16 06:00 [entrez] PHST- 2016/11/16 06:00 [pubmed] PHST- 2017/10/04 06:00 [medline] PHST- 2016/11/14 00:00 [pmc-release] AID - 10.1186/s12885-016-2942-5 [pii] AID - 2942 [pii] AID - 10.1186/s12885-016-2942-5 [doi] PST - epublish SO - BMC Cancer. 2016 Nov 14;16(1):883. doi: 10.1186/s12885-016-2942-5.